

POLARSTEM[◇]/R3[◇] best performing cementless hip combination in the UK at 10 years¹

According to the 10-year results in the 17th Annual Report 2020 of the National Joint Registry for England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey (based on cumulative percentage probability of revision)

Smith+Nephew

ODEP
7A*

POLARSTEM
Uncemented Stem²

ODEP
10A*

R3
Uncemented Cup²

72%



Lower revision risk with POLARSTEM/R3 compared to class average for cementless hip combinations at 10 years¹

0
10
years

98.46%
Highest survivorship of any cementless hip combination¹

Stem / cup brand	n	Median (IQR) age at primary	Percentage (%) males	Cumulative percentage probability of revision (95% CI) at:					
				1 year	3 years	5 years	10 years	13 years	15 years
Uncemented	444,739	-	-	0.97 (0.94-1.00)	1.80 (1.76-1.84)	2.66 (2.61-2.71)	5.52 (5.42-5.62)	7.50 (7.33-7.67)	8.75 (8.49-9.01)
Accolade™/Trident™	27,016	66 (59-73)	44	0.94 (0.83-1.07)	1.90 (1.74-2.07)	2.56 (2.37-2.77)	4.23 (3.94-4.55)	5.63 (5.04-6.29)	6.29 (5.02-7.86)
Corail™/Duraloc™ Cementless Cup	4,002	70 (64 to 75)	39	0.75 (0.53-1.08)	1.68 (1.32-2.13)	2.47 (2.02-3.01)	5.45 (4.74-6.26)	8.83 (7.79-10.01)	11.43 (10.00-13.06)
Corail/Pinnacle™	163,061	66 (59 to 73)	45	0.78 (0.74-0.82)	1.51 (1.45-1.57)	2.23 (2.15-2.32)	5.00 (4.83-5.17)	6.99 (6.69-7.31)	8.18 (7.48-8.93)
Corail/Trilogy™	3,195	68 (61 to 74)	40	0.60 (0.39-0.95)	1.07 (0.76-1.50)	1.58 (1.18-2.10)	3.05 (2.41-3.86)	3.56 (2.74-4.63)	3.56 (2.74-4.63)
Furlong HAC™ Stem/CSF™	17,076	69 (63 to 76)	40	1.10 (0.95-1.27)	1.81 (1.62-2.03)	2.19 (1.98-2.43)	3.61 (3.31-3.93)	4.36 (4.01-4.75)	5.35 (4.85-5.91)
SL-PLUS [◇] Cementless Stem/EP-FIT [◇] PLUS	5,448	66 (59 to 73)	43	1.28 (1.01-1.61)	2.69 (2.28-3.16)	3.85 (3.35-4.42)	6.15 (5.47-6.92)	7.24 (6.40-8.18)	7.95 (6.83-9.24)
Corail/ASR™ Resurfacing Cup	2,747	61 (54 to 67)	54	0.98 (0.68-1.43)	7.43 (6.50-8.48)	23.52 (21.96-25.18)	43.88 (41.98-45.82)	47.92 (45.89-50.00)	-
Taperloc™ Cementless Stem/Exceed ABT™	25,772	65 (58 to 72)	44	1.10 (0.98-1.24)	1.53 (1.38-1.69)	1.81 (1.65-1.99)	2.41 (2.17-2.67)	2.70 (2.27-3.22)	-
ANTHOLOGY [◇] /R3 Cementless	4,710	62 (54 to 69)	42	1.14 (0.87-1.49)	1.74 (1.39-2.17)	2.25 (1.82-2.78)	4.75 (3.20-7.02)	-	-
Furlong HAC Stem/Furlong HAC CSF Plus	24,159	66 (59 to 73)	45	1.11 (0.98-1.25)	1.77 (1.61-1.95)	2.07 (1.89-2.27)	2.73 (2.48-3.00)	-	-
POLARSTEM Cementless/R3 Cementless	16,088	66 (58 to 72)	46	0.74 (0.61-0.89)	0.98 (0.82-1.16)	1.26 (1.05-1.51)	1.54 (1.25-1.90)	-	-
SYNERGY [◇] Cementless Stem/R3 Cementless	3,751	65 (57 to 71)	51	0.91 (0.65-1.28)	1.32 (1.00-1.76)	1.77 (1.36-2.29)	4.12 (2.67-6.34)	-	-
Accolade II™/Trident™	10,686	65 (57 to 72)	46	0.97 (0.79-1.19)	1.50 (1.23-1.83)	1.97 (1.48-2.63)	-	-	-
Corail Pinnacle/Gription™	9,590	66 (58 to 74)	41	0.94 (0.76-1.16)	1.64 (1.37-1.96)	2.55 (2.11-3.08)	-	-	-
Furlong Evolution™ Cementless/Furlong HAC CSF Plus	4,702	62 (52 to 70)	38	1.37 (1.07-1.76)	1.91 (1.54-2.38)	2.22 (1.80-2.75)	-	-	-
Metafix™ Stem/Trinity™	6,277	64 (56 to 70)	46	0.82 (0.62-1.08)	1.23 (0.97-1.56)	1.44 (1.13-1.84)	-	-	-
M/L Taper™ Cementless/Continuum™	6,082	61 (53 to 68)	50	1.25 (1.00-1.56)	1.81 (1.50-2.19)	2.20 (1.83-2.63)	-	-	-
M/L Taper Cementless/Trilogy IT	5,198	64 (55 to 71)	51	1.24 (0.97-1.59)	2.10 (1.72-2.57)	2.42 (1.98-2.95)	-	-	-
Taperloc™ Complete Cementless Stem/Exceed ABT™	3,662	63 (56 to 70)	49	0.83 (0.58-1.19)	1.40 (1.04-1.86)	1.65 (1.23-2.21)	-	-	-

Blue italics indicate that fewer than 250 cases remained at risk at these time points.

1. National Joint Registry for England, Wales and Northern Ireland: 17th Annual Report. Available at: <http://www.njrcentre.org.uk/njrcentre>. Accessed 23 September 2020. 2. Orthopaedic Data Evaluation Panel (ODEP). Available at <http://www.odep.org.uk>. Accessed 22 September 2020

Acknowledgments: We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.